a public good project by the
Synthesis
Company
of California

© 2026

Thaddeus A. Tomaszek | doi.page

0 works0 citations0 h-index

Thaddeus A. Tomaszek

South College(US)GlaxoSmithKline (United States)(US)

Publications by Year

Research Areas

HIV/AIDS drug development and treatment, Bone Metabolism and Diseases, HIV Research and Treatment, Protease and Inhibitor Mechanisms, Natural product bioactivities and synthesis

Most-Cited Works

→ Proteolytic Activity of Human Osteoclast Cathepsin K(1996)490 cited
→ Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism(1991)245 cited
→ Potent and Selective Nonpeptide Inhibitors of Caspases 3 and 7 Inhibit Apoptosis and Maintain Cell Functionality(2000)232 cited
→ Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues(1990)231 cited
→ Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.(1989)202 cited
→ 4-Aryl-1,2,3-triazole: A Novel Template for a Reversible Methionine Aminopeptidase 2 Inhibitor, Optimized To Inhibit Angiogenesis in Vivo(2005)188 cited

→ Peptide Aldehyde Inhibitors of Cathepsin K Inhibit Bone Resorption Both In Vitro and In Vivo(1997)

185 cited

→ A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys(2006)136 cited

→ Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, x-ray crystallography, and infected T-cell assays(1992)129 cited

→ Design of potent and selective human cathepsin K inhibitors that span the active site(1997)119 cited